Pharmacogenetic and germline prognostic markers of lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 2, 2011, Pages 296-304

  Horgan, Anne M ^a   Yang, Boming ^a   Azad, Abul Kalam ^a   Amir, Eitan ^a   John, Thomas ^a   Cescon, David W ^a   Wheatley Price, Paul ^a   Hung, Rayjean J ^a   Shepherd, Frances A ^a   Liu, Geoffrey ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Lung cancer; Outcomes; Prognosis; Single nucleotide polymorphisms

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; PROTEIN MDM2; PROTEIN P53; XRCC1 PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTRON; LUNG CANCER; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79551513215     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ffe909     Document Type: Article

References (81)

1. Hopkins J, Cescon DW, Tse D, et al. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 2008;17:490-499.
2. Bosken CH, Wei Q, Amos CI, et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-1099.
3. Shellard SA, Fichtinger-Schepman AM, Lazo JS, et al. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 1993;4:491-500.
4. Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007;13:2876-2881.
5. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10:118-123.
6. de las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668-675.
7. Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009;65:230-236.
8. Sreeja L, Syamala VS, Syamala V, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol 2008;134:645-652.
9. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-2601.
10. Petty WJ, Knight SN, Mosley L, et al. A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced nonsmall cell lung cancer. J Thorac Oncol 2007;2:197-202.
11. Yoon SM, Hong YC, Park HJ, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:885-891.
12. Pillot GA, Read WL, Hennenfent KL, et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol 2006;1:972-978.
13. Wang Z, Xu B, Lin D, et al. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 2008;62:99-104.
14. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-344.
15. Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89:453-457.
16. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000;60:1305-1313.
17. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291.
18. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
19. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-4304.
20. Park SY, Hong YC, Kim JH, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 2006;23:489-498.
21. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44:311-316.
22. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007;56:281-288.
23. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010;67:101-107.
24. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1534-1538.
25. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14:1797-1803.
26. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res 2004;10:4939-4943.
27. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29:38-44.
28. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
29. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
30. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
31. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-9143.
32. Nie Q, Wang Z, Zhang GC, et al. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur J Pharmacol 2007;570:175-181.
33. Gregorc V, Hidalgo M, Spreafico A, et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 2008;83:477-484.
34. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 2007;120:1239-1247.
35. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008;8:129-138.
36. Han SW, Jeon YK, Lee KH, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenet Genomics 2007;17:313-319.
37. Ma F, Sun T, Shi Y, et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009;66:114-119.
38. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006;1:406-412.
39. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006;98:1739-1742.
40. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8:625-634.
41. Dumont P, Leu JI, Della Pietra AC III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365.
42. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-3337.
43. Sreeja L, Syamala V, Raveendran PB, et al. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest 2008;26:41-46.
44. Boldrini L, Gisfredi S, Ursino S, et al. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. Oncol Rep 2008;19:771-773.
45. Wang YC, Lee HS, Chen SK, et al. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 1999;35:226-230.
46. Han JY, Lee GK, Jang DH, et al. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799-807.
47. Matakidou A, El Galta R, Webb EL, et al. Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients. Lung Cancer 2007;57:207-212.
48. Mechanic LE, Bowman ED, Welsh JA, et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 2007;16:214-222.
49. Boldrini L, Gisfredi S, Ursino S, et al. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 2008;26:168-172.
50. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007;25:2243-2247.
51. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-5484.
52. Sweeney C, Nazar-Stewart V, Stapleton PL, et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003;12:527-533.
53. Gonlugur U, Pinarbasi H, Gonlugur TE, et al. The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 2006;24:497-501.
54. Heist RS, Marshall AL, Liu G, et al. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res 2006;12:5448-5453.
55. Jin G, Miao R, Hu Z, et al. Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. Int J Cancer 2009;124:2172-2178.
56. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237-2244.
57. Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007;110:138-147.
58. Heist RS, Zhou W, Wang Z, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5596-5602.
59. Zhou W, Heist RS, Liu G, et al. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:2239-2245.
60. Matakidou A, El Galta R, Rudd MF, et al. Prognostic significance of folate metabolism polymorphisms for lung cancer. Br J Cancer 2007;97:247-252.
61. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-2045.
62. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-862.
63. Ge H, Lam WK, Lee J, et al. Analysis of L-myc and GSTM1 genotypes in Chinese non-small cell lung carcinoma patients. Lung Cancer 1996;15:355-366.
64. Kawashima K, Nomura S, Hirai H, et al. Correlation of L-myc RFLP with metastasis, prognosis and multiple cancer in lung-cancer patients. Int J Cancer 1992;50:557-561.
65. Goto I, Yoneda S, Yamamoto M, et al. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996;56:3725-3730.
66. Haque AK, Au W, Cajas-Salazar N, et al. CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study. Appl Immunohistochem Mol Morphol 2004;12:315-322.
67. Pan JH, Han JX, Wu JM, et al. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-smallcell lung cancer. Acta Oncol 2007;46:361-366.
68. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-235.
69. Dawson E, Abecasis GR, Bumpstead S, et al. A first-generation linkage disequilibrium map of human chromosome 22. Nature 2002;418:544-548.
70. Daly MJ, Rioux JD, Schaffner SF, et al. High-resolution haplotype structure in the human genome. Nat Genet 2001;29:229-232.
71. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229.
72. Thompson D, Stram D, Goldgar D, et al. Haplotype tagging single nucleotide polymorphisms and association studies. Hum Hered 2003;56:48-55.
73. Kim HT, Lee JE, Shin ES, et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 2008;26:5972-5979.
74. Suh Y, Vijg J. SNP discovery in associating genetic variation with human disease phenotypes. Mutat Res 2005;573:41-53.
75. Wu X, Lu C, Ye Y, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008;18:955-965.
76. Matakidou A, El Galta R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 2007;16:2333-2340.
77. Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med 2007;356:1094-1097.
78. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005;6:95-108.
79. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008;299:1335-1344.
80. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-857.
81. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.